№ files_lp_4_process_2_41959
File format: docx
Character count: 93861
File size: 303 KB
The document is a Master’s Thesis that investigates psoriasis as a chronic skin condition and its significant impact on the quality of life of affected patients, focusing on nursing interventions and multidisciplinary care strategies.
Year:
2025
Region / City:
Ternopil
Theme:
Psoriasis, Nursing, Quality of Life, Chronic Disease
Organization / Institution:
I. Horbachevsky Ternopil National Medical University
Author:
Viktoriya Zhura
Target Audience:
Healthcare professionals, nursing educators, researchers
Period of Action:
2025
Approval Date:
2025
Date of Changes:
-
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2024
Region / City:
Australia
Topic:
Psoriasis Treatment
Document Type:
Patient Handout
Organization:
Victorian Government, Department of Health
Author:
Not specified
Target Audience:
Patients with mild plaque psoriasis
Period of validity:
Not specified
Approval Date:
March 2024
Amendment Date:
Not specified
Cost Information:
Free consultation; medicine costs vary based on Medicare and PBS status
Eligibility:
Adults aged 18 or older with mild plaque psoriasis
Additional Support:
Websites provided for more information
Complaint Process:
Information on complaints available at www.health.vic.gov.au/feedback-and-complaints
Safety Net Information:
Medications not included in PBS Safety Net
Consultation Details:
Private consultation with a pharmacist
Prescription Information:
Medicines under PBS or full price for non-listed items
International Students:
Eligible based on specific countries
Consent Process:
Provided during consultation
Health Advice:
Self-care and lifestyle tips included
Expected Outcome:
Symptoms should improve within 2-4 weeks
What to do if symptoms worsen:
Visit a doctor if no improvement or worsening of condition
Contact:
[email protected]
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Date:
21/01/2026
Organisation:
Bedfordshire Hospitals NHS Foundation Trust
Sites:
Bedford site; Luton site
Department:
Dermatology Department
Legislation:
Freedom of Information Act 2000
Reporting period:
October–December 2025
Definition of new patient:
Patient receiving any of the listed treatments for the first time during the reporting period, including those previously treated in 2024 or earlier years
Treatments listed:
Adalimumab (Humira and biosimilars); Etanercept (Enbrel and biosimilars); Infliximab (Remicade and biosimilars); Ustekinumab (Stelara and biosimilars); Apremilast (Otezla); Bimekizumab (Bimzelx); Brodalumab (Kyntheum); Certolizumab (Cimzia); Deucravacitinib (Sotyktu); Dimethyl Fumarate (Skilarence); Guselkumab (Tremfya); Ixekizumab (Taltz); Risankizumab (Skyrizi); Secukinumab (Cosentyx); Spesolimab (Spevigo); Tildrakizumab (Illumetri)
Data categories:
Total Dermatology Department; Psoriasis
Data format:
Numerical counts, including ranges (1–5)
Intellectual property notice:
Subject to Re-use of Public Sector Information Regulations 2015
Author:
FOI Officer
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Year:
Not specified
Region / City:
Not specified
Topic:
Clinical trial design, sample size estimation
Document type:
Educational material, study design guide
Author:
Not specified
Target audience:
Clinical researchers, study designers
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Research field:
Genetic epidemiology
Topic:
Genetic association analysis of psoriasis and psoriatic arthritis
Document type:
Research methods and supplementary materials description
Dataset:
Immunochip dataset
Genotyping centres:
Wellcome Trust Sanger Institute; Centre for Public Health Genomics at the University of Virginia; Arthritis Research UK Centre for Genetics and Genomics at the University of Manchester; University of Queensland Diamantina Institute; Trinity Translational Medicine at the University of Dublin
Genotyping software:
GenomeStudio Data Analysis Software Platform (Genotyping Module v1.8.4)
Quality control tools:
PLINK v1.07; EIGENSOFT v4.2; flashpca
Statistical methods:
Identity-by-descent analysis; principal component analysis; logistic regression; Hardy–Weinberg equilibrium filtering
Genetic markers:
SNPs from Immunochip array
Genomic region of interest:
Major Histocompatibility Complex (MHC)
Genes analyzed:
HLA-C; HLA-B; HLA-A
Phenotypes studied:
Psoriasis; Psoriatic arthritis
Population reference datasets:
HapMap3 CEU; CHB; JPT; YRI
Variables analyzed:
Allele frequency; genotype call rate; heterozygosity; age of disease onset
Associated amino acid position:
Position 45 of HLA-B
Year:
2020
Region / city:
Bangladesh
Theme:
Rights of persons with disabilities
Document type:
Report
Organization / institution:
United Nations
Author:
Committee on the Rights of Persons with Disabilities
Target audience:
Government bodies, policymakers, stakeholders in the disability sector
Period of validity:
2019–2025
Approval date:
23 December 2019
Date of amendments:
Not specified
Organization:
Schneider Electric
Document type:
Technical white paper
Authors:
Digital Plant – Industry Business, Americas Expert Support; Customer Satisfaction & Quality
Revision:
1
Product scope:
Legacy Schneider Electric PAC and PLC controllers and associated I/O, communication modules, and control networks
Lifecycle status:
Legacy products outside active cybersecurity vulnerability assessment
Industry sector:
Industrial automation and control systems
Geographic scope:
Americas
Page count:
4
Security focus:
Cybersecurity considerations for legacy control systems
Reference standards and sources:
Industrial Control Systems cybersecurity publications
Year:
2025
Region / city:
Centurion, Cape Town
Theme:
Email cleansing solution, maintenance, support, service delivery
Document type:
Request for Proposal (RFP)
Organization / institution:
SITA
Author:
SITA
Target audience:
Suppliers, bidders, technical service providers
Duration:
5 years
Approval date:
Not specified
Modification date:
Not specified
Year:
2026
Legislative session:
126th Session, 2025–2026
Jurisdiction:
South Carolina
Document type:
Senate Resolution
Legislative body:
South Carolina Senate
Sponsors:
Senators Cromer, Young, Bennett, Adams, Alexander, Allen, Blackmon, Bright, Campsen, Cash, Chaplin, Climer, Corbin, Davis, Devine, Elliott, Fernandez, Gambrell, Garrett, Goldfinch, Graham, Grooms, Hembree, Hutto, Jackson, Johnson, Kennedy, Kimbrell, Leber, Martin, Massey, Matthews, Ott, Peeler, Rankin, Reichenbach, Rice, Sabb, Stubbs, Sutton, Tedder, Turner, Verdin, Walker, Williams, Zell
Date introduced:
January 21, 2026
Date adopted:
January 21, 2026
Subject:
Recognition of the University of South Carolina
Designated observance:
Carolina Day – 225 Years of Service
Designated date:
February 17, 2026
Year:
2026
Region / City:
South Carolina, Greenville
Theme:
Fraternity Recognition, Centennial Celebration
Document Type:
House Resolution
Organ / Institution:
South Carolina House of Representatives
Author:
South Carolina House of Representatives
Target Audience:
General Public, Government, Alumni of Kappa Alpha Psi
Period of Action:
2025-2026
Date of Adoption:
January 20, 2026
Date of Changes:
None
Note:
Year
Keywords:
COVID-19, OECD, POEM
Year:
2025
Region / City:
Columbia
Theme:
Education, Workforce Development
Document Type:
Resolution
Organ / Institution:
South Carolina House of Representatives
Author:
Members of the South Carolina House of Representatives
Target Audience:
Public, Students, Educators
Period of Action:
2003–present
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / City:
Massachusetts
Subject:
Employment Policy, Criminal Record Review, Health and Human Services
Document Type:
Policy
Organization / Institution:
Executive Office of Health and Human Services (EOHHS)
Author:
Not specified
Target Audience:
Employees and applicants of EOHHS and related agencies
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2008
Region / City:
Europe
Topic:
Non-safety related Road ITS, frequency band usage
Document Type:
Recommendation
Author:
European Conference of Postal and Telecommunications Administrations (CEPT)
Target Audience:
Telecommunications Administrations of CEPT members
Period of Validity:
Ongoing, with amendments
Approval Date:
21 February 2008
Amendment Dates:
3 July 2015, 6 March 2020, 18 November 2022, 6 June 2025
Year:
2025
Region / city:
Global
Thematic area:
Disability, Gender, Social Protection
Document type:
Report
Organization / institution:
UNICEF
Author:
UNICEF
Target audience:
Policymakers, planners, implementers, communities
Period of validity:
2024–2030
Approval date:
2024
Date of changes:
2024
Contextual description:
The document provides insights and tools for addressing the challenges and support systems related to children with disabilities and their families, focusing on gendered aspects and inclusive approaches in care and development.
Year:
2018
Region / City:
Western Australia
Theme:
Electrical Asset Management, Intelligent Transport Systems
Document Type:
Policy
Organization:
Main Roads Western Australia
Author:
James Pinnington (MEAM), Andrew Martin (PESE)
Target Audience:
Main Roads Electrical Asset Management Team, Contractors, Engineers
Effective Period:
Not specified
Approval Date:
5/11/2018
Note:
Amendments
A:
5/11/2018 - Initial issue – SWEIC commence
B:
16/11/2018 - Standards Team Comments
Document number:
D17#877844
Issue date:
3 October 2017
Revision status:
Initial issue with amendments through Revision G
Owning branch:
Electrical Asset Management Branch
Organisation:
Main Roads Western Australia
Document type:
Procedure
Subject area:
Electrical and Intelligent Transport Systems asset documentation
Scope:
Asset drawing and data requirements for electrical and ITS assets
Applicable assets:
Electrical and Intelligent Transport Systems assets
Review frequency:
Five years
Owner:
James Pinnington
Custodian:
Andrew Martin
Related documents:
Electrical and ITS Asset Drawing and Data Requirements Policy; Handover of Electrical and ITS Assets Procedure; Electrical Infrastructure and Asset Drawing Guidelines
Standards referenced:
AS ISO 1000:1998; AS/NZS 3000:2007; AS 1100 Series; AS 1101 Series; AS 1102 Series
Geographic jurisdiction:
Western Australia
Year:
2024
Region / City:
Brazil
Subject:
Human Rights
Document Type:
Report
Organization:
Inter-American Commission on Human Rights (IACHR)
Author:
IACHR
Target Audience:
Governments, human rights organizations, international bodies
Effective Period:
2024
Approval Date:
2024
Date of Changes:
Not specified